News
Posted: June 21, 2019 | News
AMSINO TO ATTEND FIME 2019 IN Miami, florida
Pomona, CA - Amsino is pleased to announce their attendance at FIME 2019 IN MIAMI, FLORIDA June 26-28, 2019. Amsino stand is T74.
Please join us at our stand for the launch of our new line of water and saline products, new IV administration sets, and a new revolutionary all-in-one solidifier and liner solution for Waste Fluid Management RECEPTAL Twist!
Posted: March 29, 2019 | News, Press
AMSINO - Contributing to China’s Healthcare Industry Upgrading
Interview with Dr. Richard Y. Lee, Founder, Chairman & CEO of Amsino Medical Group
Dr. Richard Y. Lee, Founder, Chairman and CEO Amsino Medical Group, told the journalist that AMSINO was founded in 1993 and headquartered in California as a multinational medical device company that integrates R&D, manufacturing and global sales and marketing. It has 2000 employees working in 6 business divisions and 5 factories. Amsino Medical Group is aimed to improve healthcare by enhancing the safety and efficacy of patient care. It has obtained over 100 patents of internationally leading medical technologies. AMSINO medical products mainly cover: medication delivery systems, enteral nutrition feeding systems, RECEPTAL and iRECEPTAL waste fluid management systems, urological care, respiratory therapy systems, and surgical and nursing solutions. AMSINO medical products are distributed in more than 80 countries around the world besides the US. He said, "This year marks the 25th anniversary of the founding of AMSINO. Our company has undergone great changes in R&D, manufacturing and globalization. We have six business divisions, which are North America Business Division, Latin America Business Division, Europe, Middle East and Africa Business Division, Asia Pacific Business Division, China Business Division, and Contract Manufacturing Business Division. Among them, the US supports sales in North America and Latin America, Amsterdam of Netherlands supports sales in Europe, Middle East and Africa, and Shanghai of China supports sales in Asia Pacific, including Greater China Region. We attach great importance to the Chinese market which is a strategic market with unlimited business opportunities and great potential for growth. At present, our business in China accounts for about 15% of the total sales volume of the company."
Posted: October 31, 2018 | News, Press
AMSINO CLOSED THE ASSET PURCHASE AGREEMENT TO ACQUIRE SMITHS MEDICAL’S VERNON HILL’S PLANT
Pomona, CA —Amsino Medical Group is pleased to announce the closing of the previously announced Asset Purchase Agreement today with Smiths Medical ASD, Inc. (Smiths) to acquire the assets of Smiths’ manufacturing plant located in Vernon Hills, Illinois (VH). The transaction includes all assets and infrastructure that currently exist in the facility.
Posted: October 31, 2018 | News
AMSINO TO ATTEND MEDICA 2018 IN DUSSELDORF, GERMANY
Pomona, CA - Amsino is pleased to announce their attendance at MEDICA in Dusseldorf, Germany November 12-15, 2018. The Amsino stand will be in the USA Pavilion, Hall 16 E40-8.
Posted: October 26, 2018 | News, Press
Amsino receives FDA approval for hydrophillic intermittent catheters
Pomona, Ca — Amsino Medical Group announces FDA approval via a 510(k) for hydrophilic intermittent urology catheters and kits. The products are complimentary to the Amsino portfolio of urological products and utilize existing coating technologies and expertise. The hydrophilic coating will be combined with Amsino’s R-Polished® technology to a provide a superior product for self-catheterization and clinical use.
Posted: September 21, 2018 | News, Press
Amsino Medical Group to Acquire Smiths Medical’s Vernon Hills’s Manufacturing Plant
Pomona, Ca — Amsino Healthcare (USA), Inc., a fully owned subsidiary of Amsino Medical Group (“Amsino”) has signed a definitive agreement with Smiths Medical ASD, Inc. (Smiths) to acquire the assets of Smiths’ manufacturing plant located in Vernon Hills, IL (VH). The transaction includes all assets and infrastructure that currently exist in the facility. The plant has been a long-time FDA registered pharmaceutical manufacturer of essential inhalation therapy, wound care and other USP grade saline/water based products for the medical device and pharmaceutical industries. The acquisition is in alignment with Amsino’s strategic global expansion goals and its mission to improve the safety and effectiveness of patient care worldwide. The transaction is expected to close in the second half of 2018.
Posted: September 11, 2018 | News, Press
AMSure® Pre-filled Syringe for Balloon Inflation Receives FDA 510(k) Clearance
Pomona, Ca — Amsino Medical Group announces that the new AMSure® pre-filled syringe for balloon inflation with sterile water has received United States Food and Drug Administration (FDA) 510(k) clearance as a Urological Catheter and Accessories, Class II device for indwelling catheter balloon inflation applications. Amsino has expanded its manufacturing capabilities to include the production of sterile saline water products. This new clearance is a first in a series of advancements and sterile water product line extensions at Amsino.
Posted: September 11, 2018 |
AMSure® Sterile Water and Sterile Normal Saline for Wound Flush Receives FDA 510(k) Clearance
Pomona, Ca — Amsino Medical Group announces that the AMSure sterile water and sterile normal saline for wound flush has received United States Food and Drug Administration (FDA) 510(k) clearance as an unclassified pre-amendment device for both over-the-counter and prescription use, marking the expansion of Amsino manufactured saline and sterile water products in the industry.
Posted: September 10, 2018 |
Amsino’s Sure-Lok® Needle-free Connector Receives FDA 510(k) Clearance
Pomona, Ca — Amsino Medical Group Ltd. is pleased to announce that its new Sure-Lok needle-free connector has received United States Food and Drug Administration (FDA) 510(k) clearance as an Intravascular Administration Set, Class II device for I.V. administration applications. This new clearance allows Amsino to increase its product reach, further deepening the company’s overall I.V. medication delivery global platform.